Breaking News

Kite Pharma Expands R&D Team

June 11, 2014

Go and Aycock take on senior clinical ops roles

William Y. Go, M.D., Ph.D., has been appointed senior director of Clinical Development and Jeff Aycock has been named senior director of Clinical Operations at Kite Pharma
 
Prior to joining the company, Dr. Go held senior positions of increasing responsibility at Amgen, most recently as U.S. medical lead for Vectibix, medical director in Global Development. Dr. Go has co-authored 25 peer-reviewed articles and presentation abstracts. 
 
Mr. Aycock has more than 17 years of drug development experience investigating a broad range of oncology candidates in pediatric and adult settings. Mr. Aycock previously held roles of increasing responsibility during his 13 years at Amgen, where he led the Kepivance and Nplate development programs. Most recently he served as director of Oncology Study Management & U.S. Regional Lead, overseeing five oncology programs.
 
"I am delighted to announce the additions of Will Go and Jeff Aycock, each of whom brings a distinguished track record in oncology R&D within leadership roles at Amgen," said Arie Belldegrun, M.D., Kite's president and chief executive officer. "These hires continue the momentum in expanding our clinical development team, which has included the recent appointments of Dr. Jeff Wiezorek as vice president of Clinical Development and of Dr. David Chang as our new chief medical officer."

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important